Table 2.

Pharmacokinetic parameters of CO-103 and CP-103.

Compound	Route	Dose (mg/kg)	t1/2(h)	AUC0 – ∞(μM h)	F (%)	COHb AUC (%·h)	CO delivery efficiency (%)
CO-103	i.v.	5	1.1 ± 0.3	5.2 ± 0.5	100	7.0 ± 0.9	100
	p.o.	25	0.7 ± 0.1	2.4 ± 0.7	9.2	4.1 ± 0.3	11.7
	i.p.	25	1.5 ± 0.4	8.8 ± 2.4	33.8	1.3 ± 0.3	3.7
CP-103 (from CO-103)	i.v.	5	1.7 ± 0.2	8.0 ± 0.4
	p.o.	25	1.8 ± 0.3	7.7 ± 0.6
	i.p.	25	2.9 ± 0.4	10.3 ± 1.1
CP-103 (pure)	i.v.	5	0.7 ± 0.2	3.9 ± 0.2	100
	p.o.	25	1.1 ± 0.2	5.7 ± 1.4	29.2

t_1/2: terminal half-life; AUC_{0 – ∞}: area under the plasma drug concentration curve from time zero to infinity; F: bioavailability; COHb AUC: area under the curve for blood COHb level subtracting the pre-administration baseline from time zero to the last sampling time point; CO delivery efficiency: the percentage of COHb AUC in relation to that of i.v. dosing. Results are presented as the mean ± SD (n ≥ 3).